Evaluation of a long-acting injectable formulation of omeprazole in healthy dogs

被引:1
|
作者
Odunayo, Adesola [1 ]
Galyon, Gina [2 ]
Price, Joshua [3 ]
Hecht, Silke [2 ]
Tolbert, M. Katherine [4 ]
机构
[1] Univ Florida, Dept Small Anim Clin Sci, Gainesville, FL 32611 USA
[2] Univ Tennessee, Dept Small Anim Clin Sci, Knoxville, TN USA
[3] Univ Tennessee, Off Informat & Technol, Knoxville, TN USA
[4] Texas A&M Univ, Dept Small Anim Clin Sci, Gastrointestinal Lab, College Stn, TX USA
关键词
acid suppression; bravo monitoring; canine intragastric pH; proton pump inhibitor; REBOUND ACID HYPERSECRETION; PROTON PUMP INHIBITOR; INTRAGASTRIC PH; FAMOTIDINE; GASTRIN; SUPPRESSION; EFFICACY;
D O I
10.1111/jvim.16440
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background To evaluate the efficacy of a single intramuscular adminsitration of long-acting omeprazole (LA-OMEP) in increasing gastric pH in dogs. Hypothesis We hypothesized that LA-OMEP would meet in healthy dogs the clinical goals defined for human patients for treatment of gastroduodenal ulceration. Animals Nine healthy research dogs. Methods Prospective experimental study. Dogs were given a 4 mg/kg intramuscular injection of LA-OMEP. Intragastric pH was continuously recorded on treatment days 0 to 7. Daily mean pH and mean percentage time (MPT) intragastric pH was >= 3 or >= 4 were determined. Results The mean onset of action for the LA-OMEP was 98.11 min (SD 46.39). The mean number of days the dogs' pH met established goals for MPT pH >= 3 was 5.5 days (range, 3-7) and 5.25 days for MPT pH >= 4 (range, 3-7). Long-acting omeprazole met the human clinical goals pH >= 3 for 72 hours in 8/8 of the dogs and MPT pH >= 4 for 96 hours in 7/8 of dogs. Conclusions and Clinical Importance The LA-OMEP formulation produced gastric acid suppression in healthy dogs for an average of 5 days and up to 7 days, after a single intramuscular injection. No major adverse effects were observed.
引用
收藏
页码:1416 / 1421
页数:6
相关论文
共 50 条
  • [21] LONG-ACTING INJECTABLE NEUROLEPTICS
    GINESTET, D
    JULOU, L
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1982, 3 (02) : 62 - 64
  • [22] LONG-ACTING INJECTABLE NEUROLEPTICS
    GINESTET, D
    JULOU, L
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1982, 3 (07) : 277 - 277
  • [23] LONG-ACTING INJECTABLE NEUROLEPTICS
    WADDINGTON, JL
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1982, 3 (05) : 190 - 190
  • [24] LONG-ACTING INJECTABLE CONTRACEPTIVES
    不详
    LANCET, 1982, 2 (8303): : 887 - 887
  • [25] Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone
    Martin, SD
    Libretto, SE
    Pratt, DJ
    Brewin, JS
    Huq, ZU
    Saleh, BT
    CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (04) : 298 - 305
  • [26] Long-Acting Injectable Antipsychotics-A Review on Formulation and In Vitro Dissolution
    Markowicz-Piasecka, Magdalena
    Kubisiak, Marcin
    Asendrych-Wicik, Katarzyna
    Kolodziejczyk, Michal
    Grzelinska, Joanna
    Fabijanska, Malgorzata
    Pietrzak, Tomasz
    PHARMACEUTICS, 2024, 16 (01)
  • [27] Pharmacokinetics of an injectable long-acting parenteral formulation of doxycycline hyclate in pigs
    Gutierrez, L.
    Ocampo, L.
    Espinosa, F.
    Sumano, H.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2014, 37 (01) : 83 - 89
  • [28] Serum Concentrations of Paliperidone After Administration of the Long-Acting Injectable Formulation
    Helland, Arne
    Spigset, Olav
    THERAPEUTIC DRUG MONITORING, 2017, 39 (06) : 659 - 662
  • [29] More options, more value: a new long-acting injectable formulation of risperidone
    Takeuchi, Hiroyoshi
    LANCET PSYCHIATRY, 2023, 10 (12): : 911 - 913
  • [30] Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules
    Gonella, Andrea
    Grizot, Sylvestre
    Liu, Fang
    Noriega, Adolfo Lopez
    Richard, Joel
    EXPERT OPINION ON DRUG DELIVERY, 2022, 19 (08) : 927 - 944